1. Home
  2. OBE vs ALLO Comparison

OBE vs ALLO Comparison

Compare OBE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBE
  • ALLO
  • Stock Information
  • Founded
  • OBE 1979
  • ALLO 2017
  • Country
  • OBE Canada
  • ALLO United States
  • Employees
  • OBE N/A
  • ALLO N/A
  • Industry
  • OBE Oil & Gas Production
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OBE Energy
  • ALLO Health Care
  • Exchange
  • OBE Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • OBE 411.1M
  • ALLO 363.1M
  • IPO Year
  • OBE N/A
  • ALLO 2018
  • Fundamental
  • Price
  • OBE $6.12
  • ALLO $1.23
  • Analyst Decision
  • OBE Buy
  • ALLO Strong Buy
  • Analyst Count
  • OBE 2
  • ALLO 9
  • Target Price
  • OBE $11.50
  • ALLO $8.44
  • AVG Volume (30 Days)
  • OBE 337.5K
  • ALLO 3.9M
  • Earning Date
  • OBE 07-30-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • OBE N/A
  • ALLO N/A
  • EPS Growth
  • OBE N/A
  • ALLO N/A
  • EPS
  • OBE N/A
  • ALLO N/A
  • Revenue
  • OBE $501,517,751.00
  • ALLO N/A
  • Revenue This Year
  • OBE N/A
  • ALLO N/A
  • Revenue Next Year
  • OBE $2.15
  • ALLO $199.63
  • P/E Ratio
  • OBE N/A
  • ALLO N/A
  • Revenue Growth
  • OBE N/A
  • ALLO N/A
  • 52 Week Low
  • OBE $3.88
  • ALLO $0.86
  • 52 Week High
  • OBE $7.50
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • OBE 61.94
  • ALLO 43.76
  • Support Level
  • OBE $5.89
  • ALLO $1.21
  • Resistance Level
  • OBE $6.37
  • ALLO $1.50
  • Average True Range (ATR)
  • OBE 0.22
  • ALLO 0.12
  • MACD
  • OBE 0.05
  • ALLO -0.01
  • Stochastic Oscillator
  • OBE 67.06
  • ALLO 4.17

About OBE Obsidian Energy Ltd.

Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: